GlassScriptPhysician profile
Corynne A Boyer
NPI 1912138983
$4,222.40
in general payments reported to CMS, 2019-2025
29 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $1,455 · 2023: $1,590 · 2024: $490 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $896.39 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $879.81 | 2021-2024 | Xarelto |
| Cardiovascular Systems INC. | $355.72 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.83 | 2022-2023 | Jardiance |
| Smith+Nephew, INC. | $306.54 | 2021-2025 | Collagenase Santyl, Grafix Pl, Pico |
| Paratek Pharmaceuticals, INC. | $254.17 | 2024-2025 | Nuzyra |
| Scpharmaceuticals INC. | $135.19 | 2023-2025 | |
| Organogenesis INC. | $123.88 | 2024-2025 | Affinity |
| Progenacare Global, LLC | $110.40 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $87.45 | 2021-2023 | Verquvo |
| Urgo Medical North America, LLC | $82.80 | 2023-2025 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Hydrofera LLC | $72.81 | 2021-2025 | Leukomed Sorbact |
| Sanofi-Aventis U.S. LLC | $72.54 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $60.15 | 2022-2023 | Onpattro |
| Pfizer INC. | $56.78 | 2022-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $52.17 | 2022 | |
| Misonix INC | $48.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.44 | 2023 | Farxiga |
| Kerecis Limited | $36.64 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Amgen INC. | $31.99 | 2022-2025 | Repatha |
| Next Science LLC | $27.56 | 2023 | Xperience, Surgx, Blastx |
| Ovik Health, LLC | $24.33 | 2021 | |
| Grt US Holding, INC. | $23.16 | 2022 | |
| Kci USA, INC. | $21.31 | 2021 | |
| Integra Lifesciences Corporation | $21.05 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.73 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $17.38 | 2023 | Nexletol |
| United Therapeutics Corporation | $16.20 | 2022 | |
| Mimedx Group, INC. | $14.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corynne Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.